title: Treatment, outcomes, costs, and quality of life of women and men with acute coronary syndromes who have undergone percutaneous coronary intervention: results from the antiplatelet therapy observational registry.
abstract: BACKGROUND
  Treatment, outcomes, costs, and quality of life after percutaneous coronary intervention (PCI) were compared between women and men with acute coronary syndromes (ACS) using data from the Antiplatelet Therapy Observational Registry (APTOR).
  
  
  METHODS
  Fourteen European countries participated in this noninterventional, prospective, observational cohort registry, which enrolled patients with ACS who underwent PCI from 2007 to 2009. The 12-month outcomes included bleeding, cardiovascular events, and mortality. Quality of life was measured using the EQ-5D™ (EuroQol Group) health index and the visual analog scale.
  
  
  RESULTS
  The APTOR registry included 4546 patients, of whom 1047 (23%) were women and 3499 (77%) were men. The women were older (mean age, 67 vs 61 years) and had higher rates of diabetes mellitus and hypertension. A greater proportion of the men were smokers (40% vs 30%). Approximately 70% of the patients underwent PCI on the day of the qualifying ACS event. Women and men received similar medications at the time of PCI, hospital discharge, and 12-month follow-up visit. Bleeding, cardiovascular events, and mortality occurred at higher rates in women than in men, but the differences were not statistically significant. At 12 months post-PCI, women reported lower quality-of-life scores on the EQ-5D™ health index and the visual analog scale than did men. The mean total cost of care was £6252 (€7189) for women and £5841 (€6717) for men; the differences may be driven by resource use after discharge from the hospital.
  
  
  CONCLUSIONS
  Women with ACS tended to be older and had more comorbidities than men, but both sexes experienced similar outcomes after 1 year. This study indicated no differences in treatment between sexes.
authors.affiliation: Barnet and Chase Farm NHS Trust, Barnet, United Kingdom; AMORE Health, Ltd., London, United Kingdom. abakhai@tiscali.co.uk
authors.forename: Ameet
authors.initials: A
authors.lastname: Bakhai
authors.forename: Jean
authors.initials: J
authors.lastname: Ferrières
authors.forename: Stefan
authors.initials: S
authors.lastname: James
authors.forename: Andres
authors.initials: A
authors.lastname: Iñiguez
authors.forename: Attila
authors.initials: A
authors.lastname: Mohácsi
authors.forename: Gregory
authors.initials: G
authors.lastname: Pavlides
authors.forename: Mark
authors.initials: M
authors.lastname: Belger
authors.forename: Krisi
authors.initials: K
authors.lastname: Norrbacka
authors.forename: Magali
authors.initials: M
authors.lastname: Sartral
mesh_terms: D054058:Acute Coronary Syndrome / Q000191:economics / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000191:economics*; D016016:Proportional Hazards Models; D011788:Quality of Life; D012042:Registries; D012737:Sex Factors; D016896:Treatment Outcome; D055815:Young Adult